| 2.27 -1.14 (-33.43%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.32 |
1-year : | 5.4 |
| Resists | First : | 3.7 |
Second : | 4.63 |
| Pivot price | 3.6 |
|||
| Supports | First : | 2.2 |
Second : | 1.83 |
| MAs | MA(5) : | 3.21 |
MA(20) : | 3.67 |
| MA(100) : | 5.58 |
MA(250) : | 9.85 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 11.2 |
D(3) : | 14.1 |
| RSI | RSI(14): 21.7 |
|||
| 52-week | High : | 127.8 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GCTK ] has closed below the lower bollinger band by 32.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.47 | 3.47 - 3.48 |
| Low: | 2.17 - 2.18 | 2.18 - 2.2 |
| Close: | 2.25 - 2.27 | 2.27 - 2.29 |
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Thu, 29 Jan 2026
Glucotrack, Inc. Announces USPTO Approval for CBGM Patents - TradingView
Thu, 29 Jan 2026
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform - The Manila Times
Thu, 29 Jan 2026
Implantable glucose sensor designed for 3 years, backed by new US patents - Stock Titan
Tue, 30 Dec 2025
Diabetes tech firm lands $4M backing from single institutional investor - Stock Titan
Tue, 09 Dec 2025
GlucoTrack Enters Agreement to Sell Up to $20 Million of Common Shares; Stock Jumps Pre-Bell - marketscreener.com
Sat, 13 Sep 2025
GlucoTrack Stock Soars on Sixth Borough Capital Fund Investment Commitment - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 858460 (%) |
| Held by Institutions | 5.6 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -225.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.96364e+007 |
| Qtrly Earnings Growth | 268.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -2.27 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.24 |
| Dividend | 0 |
| Forward Dividend | 44500 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|